CR11267A - Preparacion solida que contiene alogliptina y clorhidrato de metformina - Google Patents
Preparacion solida que contiene alogliptina y clorhidrato de metforminaInfo
- Publication number
- CR11267A CR11267A CR11267A CR11267A CR11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alogliptine
- chlorhydrate
- metformin
- preparation containing
- solid preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion proporciona una preparacion solida que contiene el compuesto (I) es como se define en la memoria descriptiva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007188574 | 2007-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11267A true CR11267A (es) | 2010-05-03 |
Family
ID=39930391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11267A CR11267A (es) | 2007-07-19 | 2010-02-12 | Preparacion solida que contiene alogliptina y clorhidrato de metformina |
Country Status (27)
Country | Link |
---|---|
US (1) | US8900638B2 (es) |
EP (1) | EP2185138B1 (es) |
JP (2) | JP5479318B2 (es) |
KR (1) | KR101536786B1 (es) |
CN (1) | CN101801351B (es) |
AR (1) | AR067557A1 (es) |
AU (1) | AU2008276842C9 (es) |
BR (1) | BRPI0814299B8 (es) |
CA (1) | CA2694620C (es) |
CO (1) | CO6160301A2 (es) |
CR (1) | CR11267A (es) |
DO (1) | DOP2010000028A (es) |
EA (1) | EA020870B1 (es) |
EC (1) | ECSP109979A (es) |
ES (1) | ES2603879T3 (es) |
GE (1) | GEP20125672B (es) |
IL (1) | IL203171A (es) |
JO (1) | JO3272B1 (es) |
MA (1) | MA31592B1 (es) |
MY (1) | MY159203A (es) |
NZ (1) | NZ583346A (es) |
PE (2) | PE20140923A1 (es) |
TN (1) | TN2010000019A1 (es) |
TW (1) | TWI421102B (es) |
UA (1) | UA98799C2 (es) |
WO (1) | WO2009011451A1 (es) |
ZA (1) | ZA201000831B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
JO3272B1 (ar) * | 2007-07-19 | 2018-09-16 | Takeda Pharmaceuticals Co | مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد |
JP4989733B2 (ja) * | 2008-02-13 | 2012-08-01 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0917675A2 (pt) | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
CA2752437C (en) | 2009-02-13 | 2017-07-11 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
CA2755561A1 (en) | 2009-03-26 | 2010-09-30 | Mapi Pharma Limited | Process for the preparation of alogliptin |
JP5689458B2 (ja) * | 2009-05-13 | 2015-03-25 | ワイス・エルエルシー | グルコサミンを包含する栄養補助食品を安定化させる方法 |
JP5775522B2 (ja) | 2009-11-13 | 2015-09-09 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 二層錠製剤 |
DK2498759T3 (en) | 2009-11-13 | 2018-11-26 | Astrazeneca Ab | TABLE FORMULATIONS WITH IMMEDIATE RELEASE |
MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
BR112012028906A2 (pt) * | 2010-05-12 | 2016-07-26 | Mapi Pharma Ltd | polimorfos de benzoato de alogliptina |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
JP2012051832A (ja) * | 2010-08-31 | 2012-03-15 | Fancl Corp | 顆粒組成物及びそれを含有する食品又は医薬品 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013077825A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Preparation process for a formulation comprising metformin |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
EP2769712A1 (en) * | 2013-02-21 | 2014-08-27 | Siegfried International AG | Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles |
CN103353491B (zh) * | 2013-06-29 | 2018-11-16 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定苯甲酸阿格列汀原料及其制剂的方法 |
JP5922310B2 (ja) * | 2013-07-25 | 2016-05-24 | 株式会社三和化学研究所 | 医薬製剤 |
CN104749269B (zh) * | 2013-12-31 | 2018-12-28 | 中美华世通生物医药科技(武汉)有限公司 | 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法 |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
CN105527348B (zh) * | 2014-09-28 | 2018-07-24 | 中美华世通生物医药科技(武汉)有限公司 | 分离分析苯甲酸阿格列汀制剂及其有关物质的方法 |
CN104569172A (zh) * | 2014-11-05 | 2015-04-29 | 广东东阳光药业有限公司 | 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法 |
CN105675733B (zh) * | 2014-11-17 | 2020-01-31 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定琥珀酸曲格列汀及其光学异构体的方法 |
PT3227204T (pt) * | 2014-12-03 | 2020-03-26 | Caffitaly System Spa | Corpo de contenção para fabricar uma cápsula para preparar bebidas e método para fabricar cápsulas com diferentes quantidades de substância alimentar em pó utilizando um único tipo de corpo de contenção |
EP3310357A1 (en) * | 2015-06-17 | 2018-04-25 | H e x a l Aktiengesellschaft | Alogliptin formulation |
US10206923B2 (en) | 2015-08-20 | 2019-02-19 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of alogliptin and metformin |
US20180235911A1 (en) * | 2015-08-21 | 2018-08-23 | Alembic Pharmaceuticals Limited | Stable pharmaceutical composition of alogliptin and metformin fixed dose combination |
CN108366982A (zh) | 2015-10-30 | 2018-08-03 | 癌症预防制药股份有限公司 | 依氟鸟氨酸和舒林酸,固定剂量的组合制剂 |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN106008277A (zh) * | 2016-06-12 | 2016-10-12 | 聊城大学 | 一种新型二甲双胍盐酸盐及其制备方法 |
CN106421794A (zh) * | 2016-09-27 | 2017-02-22 | 黑龙江珍宝岛药业股份有限公司 | 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法 |
CN108318610A (zh) * | 2017-12-29 | 2018-07-24 | 合肥拓锐生物科技有限公司 | 一种苯甲酸阿格列汀原料及其制剂中有关物质的分析方法 |
EP3784672A4 (en) | 2018-04-27 | 2022-03-30 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | TABLET FORMULATIONS INCLUDING METFORMIN AND SITAGLIPTIN |
CN108743611A (zh) * | 2018-06-20 | 2018-11-06 | 常州制药厂有限公司 | 一种复方利血平片的制备方法 |
WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
TR201907905A1 (tr) * | 2019-05-24 | 2020-12-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Alogli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon |
CN111537622B (zh) * | 2019-11-29 | 2021-11-26 | 杭州华东医药集团新药研究院有限公司 | 一种度格列汀及其盐的杂质的检测方法 |
WO2023059118A1 (ko) * | 2021-10-08 | 2023-04-13 | (주)셀트리온 | 안정성이 개선된 당뇨병 치료용 약학 조성물 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
JPS49110814A (es) * | 1973-03-02 | 1974-10-22 | ||
WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
ES2288807T1 (es) | 1998-02-02 | 2008-02-01 | Trustees Of Tufts College | Uso de inhibidores de dipeptidasa para regular el metabolismo de la glucosa. |
ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
ITMI20002019A1 (it) | 1999-09-17 | 2002-03-15 | Novartis Ag | Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete |
JP5183844B2 (ja) | 1999-11-03 | 2013-04-17 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病の治療方法 |
US6930185B2 (en) | 2000-04-28 | 2005-08-16 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
US6403121B1 (en) | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
WO2001087834A1 (fr) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
WO2002066002A2 (en) * | 2001-02-14 | 2002-08-29 | Glaxo Wellcome S.A. | Pharmaceutical formulation |
US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
CA2452558C (en) | 2001-07-17 | 2009-12-22 | N-Gene Research Laboratories Inc. | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
EP1435931A2 (en) | 2001-09-28 | 2004-07-14 | Sun Pharmaceuticals Industries Ltd. | Dosage form for treatment of diabetes mellitus |
US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
US20030224046A1 (en) * | 2002-06-03 | 2003-12-04 | Vinay Rao | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent |
US20040125143A1 (en) | 2002-07-22 | 2004-07-01 | Kenneth Deaton | Display system and method for displaying a multi-dimensional file visualizer and chooser |
EP1543023B1 (en) | 2002-09-18 | 2010-03-17 | Prosidion Limited | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
AU2003266559B2 (en) | 2002-09-26 | 2008-01-24 | Eisai R&D Management Co., Ltd. | Combination drug |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
WO2005063226A1 (en) | 2003-12-19 | 2005-07-14 | Omega Bio-Pharma (I.P.3) Limited | Compositions and methods for treating diabetes |
CN102127053A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
KR100760430B1 (ko) | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
ES2445180T5 (es) | 2005-09-14 | 2022-02-01 | Takeda Pharmaceuticals Co | Administración de inhibidores de dipeptidil peptidasa |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CA2633167A1 (en) | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090042863A1 (en) * | 2005-12-28 | 2009-02-12 | Takeda Pharmaceutical Company Limited | Therapeutic Agent for Diabetes |
RU2333760C2 (ru) | 2006-05-16 | 2008-09-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Твердая дозированная лекарственная форма для лечения сахарного диабета |
TW200826936A (en) * | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
TW200836774A (en) * | 2007-02-01 | 2008-09-16 | Takeda Pharmaceutical | Solid preparation |
GEP20125410B (en) * | 2007-02-01 | 2012-02-27 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and pioglitazone |
JO3272B1 (ar) * | 2007-07-19 | 2018-09-16 | Takeda Pharmaceuticals Co | مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد |
RU2380097C1 (ru) | 2009-01-20 | 2010-01-27 | Общество с ограниченной ответственностью "ИТЭРА" | Твердая дозированная лекарственная форма для лечения сахарного диабета |
-
2008
- 2008-07-16 JO JOP/2008/0322A patent/JO3272B1/ar active
- 2008-07-16 UA UAA201001761A patent/UA98799C2/ru unknown
- 2008-07-16 GE GEAP200811694A patent/GEP20125672B/en unknown
- 2008-07-16 KR KR1020107003605A patent/KR101536786B1/ko active IP Right Grant
- 2008-07-16 BR BRPI0814299A patent/BRPI0814299B8/pt active IP Right Grant
- 2008-07-16 CN CN2008801080345A patent/CN101801351B/zh active Active
- 2008-07-16 JP JP2010502373A patent/JP5479318B2/ja active Active
- 2008-07-16 EP EP08791480.0A patent/EP2185138B1/en active Active
- 2008-07-16 AR ARP080103045A patent/AR067557A1/es not_active Application Discontinuation
- 2008-07-16 PE PE2013002763A patent/PE20140923A1/es active IP Right Grant
- 2008-07-16 PE PE2008001203A patent/PE20090882A1/es active IP Right Grant
- 2008-07-16 NZ NZ583346A patent/NZ583346A/en unknown
- 2008-07-16 AU AU2008276842A patent/AU2008276842C9/en active Active
- 2008-07-16 ES ES08791480.0T patent/ES2603879T3/es active Active
- 2008-07-16 EA EA201070164A patent/EA020870B1/ru unknown
- 2008-07-16 US US12/452,705 patent/US8900638B2/en active Active
- 2008-07-16 CA CA2694620A patent/CA2694620C/en active Active
- 2008-07-16 MY MYPI2010000240A patent/MY159203A/en unknown
- 2008-07-16 WO PCT/JP2008/063228 patent/WO2009011451A1/en active Application Filing
- 2008-07-16 TW TW097126889A patent/TWI421102B/zh active
-
2010
- 2010-01-06 IL IL203171A patent/IL203171A/en active IP Right Grant
- 2010-01-11 TN TNP2010000019A patent/TN2010000019A1/fr unknown
- 2010-01-19 DO DO2010000028A patent/DOP2010000028A/es unknown
- 2010-02-04 ZA ZA2010/00831A patent/ZA201000831B/en unknown
- 2010-02-05 MA MA32588A patent/MA31592B1/fr unknown
- 2010-02-12 CR CR11267A patent/CR11267A/es unknown
- 2010-02-19 CO CO10019969A patent/CO6160301A2/es unknown
- 2010-02-19 EC EC2010009979A patent/ECSP109979A/es unknown
-
2013
- 2013-11-26 JP JP2013243967A patent/JP2014058547A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11267A (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
UY31274A1 (es) | Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica | |
HN2008000188A (es) | 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion | |
DE602008000754D1 (de) | Tropanverbindungen | |
GT200800209A (es) | Compuestos organicos | |
AR059194A1 (es) | Formas de dosificacion resistentes a la manipulacion | |
CR9280S (es) | Botella | |
CR10662A (es) | Compuestos de metilpiridopirimidinona | |
CR10328A (es) | Compuestos organicos | |
HN2006037713A (es) | Compuestos utiles en terapia | |
CR11123A (es) | Compuestos triciclicos que contienen nitrogeno como agentes antibacteriales | |
SV2011003853A (es) | Compuestos organicos | |
PA8671301A1 (es) | Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización | |
GT200800276A (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
UY31563A1 (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
UY31562A1 (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
UY31560A1 (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
SV2011003800A (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica | |
CR9344S (es) | Regadera | |
UY31688A1 (es) | Plaguicidas | |
GT200500126A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
SV2009003253A (es) | Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
UY31128A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
AR082215A1 (es) | Composicion farmaceutica agradable al paladar | |
PA8846401A1 (es) | Sinergismo antibiótico |